UPDATE: Jefferies Raises PT on Allergan on Q4 EPS
Posted on February 06, 2013 at 12:52 PM EST
In a report published Wednesday, Jefferies reiterated its Hold rating on Allergan (NYSE: AGN ), and raised its price target from $95.00 to $100.00. Jefferies noted, “AGN did what it does best: beat EPS and gave strong guidance. Q4 adj-EPS of $1.15 ‘missed', but adjusting for the expected R&D tax